The new crown pneumonia Omicron variant virus has as many as 32 mutations, which makes scientists worry that existing vaccines may fail, but BioNTech, AstraZeneca, and Novavax seem to be optimistic. Among them, BioNTech said that even if it wants to produce an improved version of the vaccine , Can also be shipped within 100 days.
BioNTech said on Friday (26th) that they will collect more data in the next two weeks to evaluate whether the new crown pneumonia vaccine jointly developed with Pfizer is effective against the Omicron variant virus recently discovered in South Africa and other places, and whether it needs to respond to the virus globally Spread and improve the vaccine.
The company added that Pfizer and BioNTech can redesign their vaccines within six weeks, and the first batch can be shipped within 100 days.
AstraZeneca said that they have great hopes for the effectiveness of the antibody cocktail therapy it has developed to deal with new variant viruses. It also pointed out that experts are collecting data in Botswana and other places to examine the impact of the virus on its vaccines.
Novavax Pharmaceuticals pointed out that the second phase of the vaccine test convinced them that Novavax's vaccine is likely to be effective against the new variant virus.
The personnel have begun to develop a new recombinant spike protein based on this virus, which is believed to be tested and produced in the next few weeks.
New crown pneumonia|WHO: Only 27% of African health care providers are fully vaccinated. New crown pneumonia|WHO lists B.1.1.529 as a variant virus strain worthy of attention, named omicron African variant virus coming to Hong Kong on Saturday, an emergency ban from staying in southern Africa Entry of non-Hong Kong citizens from 8 countries B.1.1.529|Belgium reports the first confirmed case of a new variant virus in Europe